Biogaia AB

Latest Results (17.10.2025):

Biogaia AB reported its financial results for the second quarter of 2025, showing a 5% increase in net sales to SEK 404.7 million compared to the same period last year. While the Pediatrics segment experienced modest growth, the Adult Health segment demonstrated strong performance. However, operating profits declined due to increased marketing investments. The company also announced strategic initiatives to expand its global footprint.

Net Sales Growth

Biogaia AB achieved net sales of SEK 404.7 million in Q2 2025, reflecting a 5% increase compared to SEK 384.1 million in Q2 2024. Year-to-date net sales rose by 5% to SEK 771.0 million from SEK 753.9 million, excluding foreign exchange effects.

Segment Performance

The Adult Health segment saw a significant increase in net sales, up 15% to SEK 89.8 million in Q2 2025 and 20% year-to-date to SEK 184.4 million. In contrast, the Pediatrics segment experienced a modest growth of 2% in Q2 2025 to SEK 310.1 million, while year-to-date sales slightly declined by 3% to SEK 580.0 million.

Operating Profit Decline

Operating profits decreased by 20% to SEK 108.3 million in Q2 2025 from SEK 135.4 million in the previous year, resulting in an operating margin of 27% compared to 35%. Year-to-date operating profit also fell by 26% to SEK 205.5 million.

Increased Marketing Investments

The decline in operating profit is attributed to a 23% increase in operating expenses for Q2 2025, reaching SEK 185.5 million. Year-to-date operating expenses rose by 31% to SEK 356.8 million, driven by enhanced marketing efforts and the expansion of direct sales channels.

Strategic Expansion

Following the end of Q2 2025, Biogaia AB launched a subsidiary, BioGaia New Sciences AB, to advance its microbiome research and establish direct sales in the Netherlands. Additionally, the company converted 1,038,202 Class A shares into Class B shares, resulting in a decrease in the number of voting shares.